US NIH stops ACTIV-2 phase 3 trial of Covid-19 drug candidate SAB-185
SAB Biotherapeutics said that the US National Institutes of Health (NIH) is discontinuing the phase 3 ACTIV-2 trial of the company’s SAB-185 for the treatment ... Read More
SAB Biotherapeutics begins phase 1b Covid-19 trial of SAB-185
SAB Biotherapeutics, a US biopharma company, said that the first patient in a phase 1b clinical trial of its investigational Covid-19 therapeutic SAB-185 has been ... Read More